Gene Vectors Market Predicted to Rise at a 12.6% CAGR until 2031, Reaching US$ 3.4 billion: TMR Report
October 30, 2023 04:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - TMR predicted that the gene vector market is likely to reach US$ 3.4 billion by 2031. Gene...
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease
June 01, 2023 05:09 ET
|
Rentschler Biopharma SE
Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...
Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs
September 14, 2022 07:00 ET
|
Oxford Biomedica Solutions LLC
Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs Bedford, Massachusetts – September 14, 2022: Oxford Biomedica Solutions LLC, an Oxford...
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
April 26, 2022 03:00 ET
|
ViGeneron GmbH
The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ...
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
January 18, 2021 02:00 ET
|
ViGeneron GmbH
MUNICH, Germany, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV)...
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
January 05, 2021 02:00 ET
|
ViGeneron GmbH
Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional targetThe companies will use ViGeneron’s proprietary vgAAV...